截至 2026-09-30(2026-11-16 向 SEC 提交的 13F),Julian & Felix Baker(贝克兄弟) 管理的 Baker Bros. Advisors(贝克兄弟顾问) 披露 79 只美股持仓,申报总市值 $21.04B。前五大持仓:INCY 17.8%、ONC 15.4%、RVMD 10.4%、KOD 9.9%、MDGL 5.1%。本期变化:新建仓 TRAX、SCTX、FRNM、QTTB;清仓 CRINETICS PHAR、ALMS、VRDN、SION、VSTM、SGMT、WVE、SURROZEN, INC.;主要加仓 KOD、CLDX、ONC、MPLT、DSGN;主要减仓 CELC、RVMD、IMVT、IONS、STOK。
朱利安·贝克(Julian Baker)与费利克斯·贝克(Felix Baker)兄弟 2000 年在纽约创立贝克兄弟顾问(Baker Bros. Advisors),专注生物科技,长期集中持有,常持有被投公司较高比例股份。13F 只披露美股多头。与站内的 Gavin Baker(Atreides)无关。
| # | 代码 | 公司 | 权重 | 市值 | 股数 | 本期 |
|---|---|---|---|---|---|---|
| 1 | INCY | Incyte Corporation | 17.8% | $3.73B | 30,762,652 | 加仓 |
| 2 | ONC | 百济神州 (BeOne Medicines) | 15.4% | $3.23B | 8,832,335 | 加仓 |
| 3 | RVMD | Revolution Medicines, Inc. | 10.4% | $2.18B | 10,637,318 | 减仓 |
| 4 | KOD | Kodiak Sciences Inc. | 9.9% | $2.07B | 21,860,941 | 加仓 |
| 5 | MDGL | Madrigal Pharmaceuticals, Inc. | 5.1% | $1.08B | 2,143,131 | 持有 |
| 6 | INSM | Insmed Incorporated | 4.8% | $1.00B | 8,796,111 | 持有 |
| 7 | KYMR | Kymera Therapeutics, Inc. | 4.6% | $967.79M | 8,657,242 | 持有 |
| 8 | ACAD | Acadia Pharmaceuticals Inc. | 4.1% | $864.70M | 42,912,904 | 持有 |
| 9 | GRAL | GRAIL, Inc. | 2.7% | $564.49M | 4,028,614 | 持有 |
| 10 | SMMT | Summit Therapeutics Inc. | 2.6% | $554.42M | 32,786,348 | 持有 |
| 11 | RYTM | Rhythm Pharmaceuticals, Inc. | 2.5% | $533.63M | 5,604,483 | 持有 |
| 12 | PRAX | Praxis Precision Medicines, Inc. | 2.4% | $510.58M | 1,753,198 | 持有 |
| 13 | ABCL | AbCellera Biologics Inc. | 2.3% | $481.65M | 33,012,139 | 加仓 |
| 14 | ALKS | Alkermes plc | 1.9% | $405.70M | 10,012,267 | 持有 |
| 15 | CELC | Celcuity Inc. | 1.8% | $382.95M | 4,815,792 | 减仓 |
| 16 | KNSA | Kiniksa Pharmaceuticals International, plc | 1.0% | $211.49M | 2,834,643 | 持有 |
| 17 | IDYA | IDEAYA Biosciences, Inc. | 0.9% | $192.49M | 5,010,030 | 持有 |
| 18 | EWTX | Edgewise Therapeutics, Inc. | 0.7% | $150.29M | 3,701,719 | 持有 |
| 19 | REPL | Replimune Group, Inc. | 0.7% | $146.24M | 11,045,336 | 持有 |
| 20 | ROIV | Roivant Sciences Ltd. | 0.6% | $133.86M | 3,660,352 | 减仓 |
| 21 | ARWR | Arrowhead Pharmaceuticals, Inc. | 0.5% | $111.86M | 1,709,053 | 减仓 |
| 22 | NRIX | Nurix Therapeutics, Inc. | 0.5% | $110.45M | 4,658,556 | 持有 |
| 23 | IMVT | Immunovant, Inc. | 0.4% | $93.58M | 2,770,377 | 减仓 |
| 24 | CLDX | Celldex Therapeutics, Inc. | 0.4% | $83.13M | 2,564,984 | 加仓 |
| 25 | DNLI | Denali Therapeutics Inc. | 0.4% | $77.19M | 3,734,336 | 持有 |
| 26 | DNTH | Dianthus Therapeutics, Inc. | 0.4% | $75.03M | 852,164 | 持有 |
| 27 | RAPP | Rapport Therapeutics, Inc. | 0.2% | $51.98M | 1,547,090 | 持有 |
| 28 | GLUE | Monte Rosa Therapeutics, Inc. | 0.2% | $51.84M | 4,345,736 | 持有 |
| 29 | RLAY | Relay Therapeutics, Inc. | 0.2% | $51.02M | 2,826,783 | 持有 |
| 30 | IONS | Ionis Pharmaceuticals, Inc. | 0.2% | $45.72M | 1,023,864 | 减仓 |
数据来源:SEC EDGAR 13F-HR 公开申报。13F 只披露季度末的美股多头仓位,提交期限为季度结束后 45 天,不含空头、现金和非美股资产;不构成投资建议。 原始申报:SEC EDGAR 0001104659-26-128308。 机器可读数据:baker-bros.json。